Sacubitril

Sacubitril is a neprilysin inhibitor used in combination with valsartan for the treatment of heart failure with reduced ejection fraction.

Indications

Treatment of chronic heart failure (NYHA Class II-IV) in patients with reduced ejection fraction

Dosage

The recommended starting dose is Sacubitril/Valsartan 49/51 mg twice daily, which can be uptitrated to Sacubitril/Valsartan 97/103 mg twice daily after 2-4 weeks.

Contra-Indications

-Concomitant use with ACE inhibitors. -History of angioedema related to previous ACE inhibitor or ARB therapy.

Special Precautions

-Renal impairment. -Hypotension. -Hyperkalemia. -Dual blockade of the renin-angiotensin-aldosterone system (RAAS).

Side Effects

-Hypotension. -Hyperkalemia. -Renal impairment. -Angioedema.

Drug Interactions

-ACE inhibitors. -Potassium-sparing diuretics. -Non-steroidal anti-inflammatory drugs (NSAIDs).